5 Recent Studies on Doxorubicin and its Analogues

N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice

“…Data shown in Figure 4b indicate a rate of non-specific clearance of Conjugate 2 to be equivalent to 3-4% plasma volume/h-'; therefore other factors (such as non-specific adsorptive pinocytosis) may also contribute to the liver capture of galactose-targeted HPMA copolymer-DOX conjugates. This would not be surprising in view of the affinity of DOX for interaction with membranes (Brown & Imam, 1984).…”

Recent Clinical Successes in Liposomal Nanomedicines

“…The FDA has approved 132 anticancer drugs, with anthracycline as the main class [23]. Since its first discovery in the 1960s, doxorubicin remains the most widely used chemotherapy drug, demonstrating broad-spectrum anticancer activity against hematologic and solid tumours [24]. Unfortunately, despite its wide applications, the long-term clinical use of doxorubicin has been restricted due to its toxic side effects.…”

“…Clinical data showed that up to 26% of patients receiving conventional doxorubicin developed arrhythmias, atrial and ventricular, which may progress to congestive heart failure (CHF) [27][28][29][30]. A cumulative dose of doxorubicin from 550 to 700 mg/m 2 can increase the CHF rate from 5% to 48% [24][25][26]. Other common doxorubicin-induced toxicity effects are acute nausea and vomiting, stomatitis, and myelosuppression [24,31,32].…”

“…A cumulative dose of doxorubicin from 550 to 700 mg/m 2 can increase the CHF rate from 5% to 48% [24][25][26]. Other common doxorubicin-induced toxicity effects are acute nausea and vomiting, stomatitis, and myelosuppression [24,31,32]. Given the severe side effects, efforts have been made to improve the therapeutic index of conventional doxorubicin, including low-dose infusion regimens, new drug discovery, and drug nanocarriers [33][34][35].…”